NG2 (CSPG4) has been implicated in various cancers, including melanoma, glioblastoma and thyroid cancer, where its high expression correlates with poor prognosis due to its support of tumor growth, angiogenesis and resistance to therapies (65). This evidence concerns the gene CSPG4 and glioblastoma.